Synergy of dissolving microneedles and ultrasound to enhance transdermal delivery for rheumatoid arthritis
- PMID: 40372697
- DOI: 10.1007/s13346-025-01876-y
Synergy of dissolving microneedles and ultrasound to enhance transdermal delivery for rheumatoid arthritis
Abstract
Dissolving microneedles (DMNs) are an emerging transdermal drug delivery system that has gained increasing attention as an alternative to traditional oral and injectable methods for treating rheumatoid arthritis (RA). However, these DMNs encounter challenges related to insufficient drug diffusion through passive mechanisms. To address this issue, we developed biocompatible DMNs fabricated from hyaluronic acid (HA) loaded with ultrasound-responsive nanoparticles, aiming at enhancing drug permeation and diffusion through ultrasound (US) assistance. Methotrexate (MTX), a first-line treatment for RA, was encapsulated in poly (lactic-co-glycolic acid) (PLGA)-based nanoparticles containing perfluoro-n-pentane (PFP), referred to as MTX-PFP-NPs. These nanoparticles were then incorporated into DMNs, designated as MTX-PFP-NPs@DMNs. Under the cavitation effect of ultrasound, PFP undergoes a phase transition that facilitates drug release and diffusion. The synergistic effect of the DMNs system and US were demonstrated in both an ex-vivo rat skin model and a collagen-induced arthritis (CIA) mouse model. The MTX-PFP-NPs@DMNs exhibited sufficient mechanical strength to penetrate the stratum corneum and dissolve completely within 20 min, enabling effective drug delivery. The synergistic effect of the DMNs system and US was evidenced by enhanced FITC penetration and diffusion in the ex-vivo rat skin model. Additionally, in vivo studied showed improved therapeutic efficacy in reducing joint swelling, bone erosion, cartilage damage, and pro-inflammatory cytokines level compared to only MTX-PFP-NPs@DMNs. This research underscores the promising integration of DMNs technology and US, offering a high-compliance approach to transdermal drug delivery that could significantly improve treatment outcomes for chronic conditions like RA.
Keywords: Dissolving microneedles; Drug diffusion; Rheumatoid arthritis; Transdermal drug delivery; Ultrasound-responsive.
© 2025. Controlled Release Society.
Conflict of interest statement
Declarations. Ethics approval: All animal experimental procedures were approved by the Ethics Committee on Laboratory Animals of the University of South China. Consent for publication: Not applicable. Competing interests: All authors have agreed with publication of the manuscript.
Similar articles
-
Mechanical strength affecting the penetration in microneedles and PLGA nanoparticle-assisted drug delivery: Importance of preparation and formulation.Biomed Pharmacother. 2024 Apr;173:116339. doi: 10.1016/j.biopha.2024.116339. Epub 2024 Feb 29. Biomed Pharmacother. 2024. PMID: 38428314
-
Flexible two-layer dissolving and safing microneedle transdermal of neurotoxin: A biocomfortable attempt to treat Rheumatoid Arthritis.Int J Pharm. 2019 May 30;563:91-100. doi: 10.1016/j.ijpharm.2019.03.033. Epub 2019 Mar 16. Int J Pharm. 2019. PMID: 30890451
-
Dissolving microneedles: A transdermal drug delivery system for the treatment of rheumatoid arthritis.Int J Pharm. 2025 Feb 25;671:125206. doi: 10.1016/j.ijpharm.2025.125206. Epub 2025 Jan 10. Int J Pharm. 2025. PMID: 39799999 Review.
-
Dissolving microneedle patch-assisted transdermal delivery of methotrexate improve the therapeutic efficacy of rheumatoid arthritis.Drug Deliv. 2023 Dec;30(1):121-132. doi: 10.1080/10717544.2022.2157518. Drug Deliv. 2023. PMID: 36533887 Free PMC article.
-
Dissolving microneedles: Drug delivery and disease treatment.Colloids Surf B Biointerfaces. 2025 Jun;250:114571. doi: 10.1016/j.colsurfb.2025.114571. Epub 2025 Feb 17. Colloids Surf B Biointerfaces. 2025. PMID: 39983455 Review.
Cited by
-
Tie2-mediated CBL ubiquitination of EGFR underlies ultrasound-responsive silk fibroin/graphene oxide hydrogel-troxerutin therapy for intervertebral disc degeneration.Mater Today Bio. 2025 Jul 29;34:102149. doi: 10.1016/j.mtbio.2025.102149. eCollection 2025 Oct. Mater Today Bio. 2025. PMID: 40791793 Free PMC article.
References
-
- Di Matteo A, Bathon JM, Emery P. Rheumatoid arthritis. Lancet. 2023;402(10416):2019–33. https://doi.org/10.1016/s0140-6736(23)01525-8 . - DOI - PubMed
-
- Xu Y, Zhao M, Cao J, Fang T, Zhang J, Zhen Y, et al. Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis. Acta pharmaceutica Sinica B. 2023;13(11):4417–41. https://doi.org/10.1016/j.apsb.2023.05.025 . - DOI - PubMed - PMC
-
- An X, Yang J, Cui X, Zhao J, Jiang C, Tang M, et al. Advances in local drug delivery technologies for improved rheumatoid arthritis therapy. Adv Drug Deliv Rev. 2024;209:115325. https://doi.org/10.1016/j.addr.2024.115325 . - DOI - PubMed
-
- Dogra S, Singh N, Kumar S, Narang T, Handa S. Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis. Dermatol Ther. 2022;35(8):e15656. https://doi.org/10.1111/dth.15656 . - DOI - PubMed
-
- Sheng T, Luo B, Zhang W, Ge X, Yu J, Zhang Y, et al. Microneedle-mediated vaccination: innovation and translation. Adv Drug Deliv Rev. 2021;179:113919. https://doi.org/10.1016/j.addr.2021.113919 . - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources